GE MEDICAL SYSTEMS

DeepHealth, a RadNet subsidiary, received expanded FDA 510(k) clearance for its mammography software, SmartMammo Dx, now compatible with GE HealthCare's Senographe Pristina systems. Initially cleared in 2021 for Hologic systems, the AI algorithm has also been tested and cleared for patients with unilateral breasts and implants.

SmartMammo Dx, an AI tool for breast cancer detection with digital breast tomosynthesis (DBT), received expanded FDA clearance for use with GE HealthCare's Senographe Pristina mammography platforms. The software assigns suspicion levels for breast cancer based on soft tissue lesions and calcifications, enhancing detection rates in women with dense breasts and African American women.

RadNet's DeepHealth subsidiary expands FDA clearance for SmartMammo™ Dx AI algorithm to include GE HealthCare's Senographe Pristina™ systems, enhancing breast cancer screening accuracy and system compatibility.

RadNet's DeepHealth subsidiary receives expanded FDA 510(k) clearance for SmartMammo Dx AI algorithm, now compatible with GE HealthCare's Senographe Pristina™ mammography systems, enhancing cancer detection accuracy and operational efficiency.

The AI in precision medicine market is expected to grow from USD 172.4 million in 2024 to USD 377.1 million by 2029, driven by customized treatments, genomics advancements, and drug development acceleration. Key players include NVIDIA, Google, Microsoft, and others, who use strategies like acquisitions and product innovations to enhance personalized care and treatment predictions.

AI in precision medicine market to reach USD 377.1 million by 2029, driven by advanced technologies and personalized care needs. Software dominates due to data analysis and predictive modeling. Oncology leads in therapeutic areas, aided by AI's ability to interpret complex data. North America leads with sophisticated healthcare systems and significant R&D investments. Key players include NVIDIA, Google, Microsoft, IBM, and Tempus.

Zhang Yihao, GE HealthCare China CEO, believes the Chinese supply chain system is a powerful global solution, showcased at the second China International Supply Chain Expo. GE HealthCare highlighted its domestic supply chain's achievements in high-end medical equipment, emphasizing supplier innovation and integration. The company's seven factories in China collaborate with supply chain partners, fostering industrial clusters and nurturing 'little giant' firms. Zhang sees the expo as a platform for industry integration, innovation, and market interconnectivity, promoting mutual integration and shared prosperity of supply chains globally.

Cell Expansion Market to grow at 14.9% CAGR from USD 12.45 billion in 2023 to USD 43.44 billion in 2030, driven by chronic diseases and regenerative medicine. Key players include Thermo Fisher Scientific and Merck KGaA. Asia-Pacific expected to lead growth due to biotech investments.